Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANK-003 + Adjuvant Chemotherapy in Stage IIIA NSCLC
NCT07043907Phase 2Not yet recruiting
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
A Phase 2 trial of PANK-003 in non-small cell lung cancer (NSCLC), sponsored by Shenzhen Celconta Life Science Co., Ltd.. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
PANK-003
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07043907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043907.